Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) involves motoneuron vulnerability due to protein misfolding, aggregation, and mitochondrial dysfunction.
• Mutant copper-zinc superoxide dismutase (SOD1) aggregation is implicated in ALS pathogenesis, but its exact role remains debated.
• Glutaredoxins (Grxs) are enzymes that can restore redox balance by reducing protein disulfides.

Purpose of the Study:

• To investigate the role of glutaredoxins (Grxs) in mitigating mutant SOD1 toxicity in motoneurons.
• To determine whether Grx1 or Grx2 is more effective in preventing mutant SOD1 aggregation and subsequent neuronal damage.
• To explore the potential of targeting mitochondrial function for ALS therapy.

Main Methods:

• Overexpression of Grx1 and Grx2 in neuronal cell models (SH-SY5Y and NSC-34) expressing mutant SOD1.
• Assessing the solubility of mutant SOD1 in different cellular compartments (cytosol and mitochondria).
• Evaluating mitochondrial integrity, function, and apoptosis markers in response to Grx overexpression.

Main Results:

• Grx1 overexpression increased cytosolic mutant SOD1 solubility but did not prevent mitochondrial damage or apoptosis.
• Grx2 overexpression increased mitochondrial mutant SOD1 solubility, preserved mitochondrial function, and reduced apoptosis.
• Grx2 modulated proteins involved in mitochondrial dynamics, mitigating fragmentation and protecting neuronal cells.

Conclusions:

• Mitochondrial dysfunction is a primary driver of mutant SOD1 toxicity in ALS.
• Targeting mitochondrial integrity and function with Grx2 shows therapeutic potential for ALS.
• Restoring mitochondrial health represents a promising strategy for combating ALS.